EP3335703A1 — Pharmaceutical composition comprising omarigliptin
Assigned to Hexal AG · Expires 2018-06-20 · 8y expired
What this patent protects
The present invention relates to a pharmaceutical composition comprising omarigliptin or a pharmaceutically acceptable salt thereof and less than 75% by weight of neutral excipients, a process for preparing the pharmaceutical composition and its use in the treatment of type 2 dia…
USPTO Abstract
The present invention relates to a pharmaceutical composition comprising omarigliptin or a pharmaceutically acceptable salt thereof and less than 75% by weight of neutral excipients, a process for preparing the pharmaceutical composition and its use in the treatment of type 2 diabetes mellitus.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.